NZ752298A - Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x - Google Patents

Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x

Info

Publication number
NZ752298A
NZ752298A NZ752298A NZ75229817A NZ752298A NZ 752298 A NZ752298 A NZ 752298A NZ 752298 A NZ752298 A NZ 752298A NZ 75229817 A NZ75229817 A NZ 75229817A NZ 752298 A NZ752298 A NZ 752298A
Authority
NZ
New Zealand
Prior art keywords
coagulation factor
antibody
administered
weeks
blood coagulation
Prior art date
Application number
NZ752298A
Other versions
NZ752298B2 (en
Inventor
Koichiro Yoneyama
Christophe Schmitt
Original Assignee
Hoffmann La Roche
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61561893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ752298(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Chugai Pharmaceutical Co Ltd filed Critical Hoffmann La Roche
Publication of NZ752298A publication Critical patent/NZ752298A/en
Publication of NZ752298B2 publication Critical patent/NZ752298B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed is the use of a bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X for the treatment of hemophilia A, acquired hemophilia A, von Willebrand disease or hemophilia A with emergence of an inhibitor against FVIII and/or FVIIIa, according to a given dosage regimen.

Claims (11)

CLAIMS ]
1. [Claim 1] Use of a bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X in the manufacture of a medicament for treating and/or reducing the incidence of a disease that develops and/or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII (FVIII) and/or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody is to be administered subcutaneously to a subject at a weekly loading dose of 3 mg/kg of the antibody for four weeks; and, after the loading dose administrations are complete, a maintenance dose of the antibody is to be subcutaneously administered to the subject one or more times, wherein the maintenance dose is 6 mg/kg of the antibody that is to be administered to the subject every four weeks in a single dose or multiple divided doses, wherein the maintenance dose is to be administered (i) in one single dose at 6 mg/kg of the antibody every four weeks; or (ii) in two single doses each at 3 mg/kg of the antibody every four weeks, wherein one single dose of the maintenance dose at 3 mg/kg of the antibody is administered once every two weeks, wherein the disease is hemophilia A, acquired hemophilia A, von Willebrand disease, or hemophilia A with emergence of an inhibitor against FVIII and/or FVIIIa and wherein the bispecific antibody (A) comprises a first polypeptide which is an H chain containing an H chain variable region amino acid sequence of SEQ ID NO: 4; a second polypeptide which is an H chain containing an H chain variable region amino acid sequence of SEQ ID NO: 9; and a third and fourth polypeptide which are a commonly shared L chain containing an L chain variable region amino acid sequence of SEQ ID NO: 14; or (B) comprises a first polypeptide which is an H chain containing the amino acid sequence of SEQ ID NO: 5; a second polypeptide which is an H chain containing the amino acid sequence of SEQ ID NO: 10; and a third and fourth polypeptide which are a commonly shared L chain containing the amino acid sequence of SEQ ID NO: 15.
2. [Claim 2] The use of claim 1, wherein the bispecific antibody is emicizumab.
3. [Claim 3] The use of claim 1, wherein the maintenance dose is to be administered in one single dose at 6 mg/kg of the antibody every four weeks.
4. [Claim 4] The use of claim 1, wherein the maintenance dose is to be administered in two single doses of the antibody each at 3 mg/kg of the antibody every four weeks, wherein one single dose at 3 mg/kg of the antibody is to be administered once every two weeks.
5. [Claim 5] The use of claim 1, wherein the maintenance doses are to be administered to the subject over multiple four-week periods.
6. [Claim 6] The use of claim 1, wherein the disease is hemophilia A.
7. [Claim 7] The use of claim 1, wherein the disease is acquired hemophilia A.
8. [Claim 8] The use of claim 1, wherein the disease is von Willebrand disease.
9. [Claim 9] The use of claim 1, wherein the disease is hemophilia A with emergence of an inhibitor against blood coagulation factor VIII and/or activated blood coagulation factor VIII.
10. [Claim 10] The use of claim 1, wherein the maintenance doses are to be administered until at least 52 weeks have elapsed after the first loading dose was administered.
11. [Claim 11] The use of any one of claims 1 to 10, substantially as herein described, with reference to any example thereof and with reference to the appended figures.
NZ752298A 2017-09-05 Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x NZ752298B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662383933P 2016-09-06 2016-09-06
US201662437281P 2016-12-21 2016-12-21
US201762485514P 2017-04-14 2017-04-14
PCT/JP2017/031933 WO2018047813A1 (en) 2016-09-06 2017-09-05 Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x

Publications (2)

Publication Number Publication Date
NZ752298A true NZ752298A (en) 2025-02-28
NZ752298B2 NZ752298B2 (en) 2025-06-04

Family

ID=

Also Published As

Publication number Publication date
EP3509637B1 (en) 2024-11-27
AU2024204924A1 (en) 2024-08-08
WO2018047813A1 (en) 2018-03-15
RU2766233C2 (en) 2022-02-10
EP3509637A4 (en) 2020-05-27
PL3509637T3 (en) 2025-03-10
IL265144B2 (en) 2024-10-01
MY209831A (en) 2025-08-07
RU2019109464A3 (en) 2020-12-21
MX2019002510A (en) 2019-06-24
US11352438B2 (en) 2022-06-07
JP2019530654A (en) 2019-10-24
EP3509637A1 (en) 2019-07-17
IL265144A (en) 2019-04-30
AU2017325240B2 (en) 2024-08-08
TW201822815A (en) 2018-07-01
US20220315667A1 (en) 2022-10-06
AU2017325240B9 (en) 2025-02-13
EP4491224A3 (en) 2025-04-23
CR20190162A (en) 2019-05-13
JP2022166174A (en) 2022-11-01
CN109661241A (en) 2019-04-19
MA46200A (en) 2019-07-17
SG11201901961SA (en) 2019-04-29
JP7125932B2 (en) 2022-08-25
KR20230117462A (en) 2023-08-08
US20240052058A1 (en) 2024-02-15
TWI786061B (en) 2022-12-11
EP4491224A2 (en) 2025-01-15
AU2017325240A1 (en) 2019-05-02
CA3035327A1 (en) 2018-03-15
US20190194352A1 (en) 2019-06-27
KR20190044673A (en) 2019-04-30
BR112019003989A2 (en) 2019-05-28
KR102560808B1 (en) 2023-07-27
JP2024161483A (en) 2024-11-19
ES3000618T3 (en) 2025-03-03
RU2019109464A (en) 2020-10-08
IL265144B1 (en) 2024-06-01
US20230159658A1 (en) 2023-05-25
UA129116C2 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
RU2017101705A (en) PHARMACEUTICAL COMPOSITION INTENDED FOR APPLICATION FOR PREVENTION AND / OR TREATMENT OF A DISEASE THAT IS DEVELOPING OR PROGRESSING AS A RESULT OF REDUCTION OR LOSS OF SURVIVAL FACTOR
RU2019109464A (en) METHODS OF APPLICATION OF A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND / OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND / OR ACTIVATED COAGULATION FACTOR X
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
FI3793588T3 (en) Methods of treating hemophilia a
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
FI3227675T3 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
RU2016151757A (en) PDL-1 AND PD-1 ANTAGONISTS FOR TREATMENT OF HPV-NEGATIVE CANCER FORMS
JP2016514132A5 (en)
IL292193B2 (en) Anti-B7-H1 antibodies for the treatment of tumors
JP2018509388A5 (en)
JP2019501886A5 (en)
JP2016516073A5 (en)
RU2014100107A (en) TREATMENT OF BLOOD COAGULATION DISORDERS BY INTRODUCING RECOMBINANT EF
EP3062809B1 (en) A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP4424366A3 (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
ZA202106768B (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
JOP20190019A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
MX2021009114A (en) Methods of prophylactic treatment using recombinant vwf (rvwf).
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
NZ752298B2 (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
JP2018522881A5 (en)
RU2018132694A (en) PHARMACEUTICAL COMPOSITION, INCLUDING RECOMBINANT HUMAN GROWTH HORMONE FOR TREATMENT OF GROWTH HORMONE DEFICIENCY
BR112021018219A2 (en) Method of treatment of infective endocarditis
AR099907A1 (en) PHARMACEUTICAL COMPOSITION USED IN THE PREVENTION AND / OR TREATMENT OF DISEASES CAUSED AND / OR AGGRAVATED BY A DECREASE OR DEFICIENCY OF THE ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND / OR THE ACTIVATED BLOOD COAGULATION FACTOR VIII

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2026 BY DENNEMEYER + CO. SARL

Effective date: 20250826